A Phase 2 interventional study of VIB4920 and Placebo in Sjögren's Syndrome, sponsored by Amgen. Completed at 63 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2019, is one of 30 in phase 2, and was the 66th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
Vor Biopharma · Sites in United States, Georgia
Ages 18–75
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 7 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score \< 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.
Study acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Drug: VIB4920 · Drug: Placebo
Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Drug: VIB4920 · Drug: Placebo
Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Drug: VIB4920 · Drug: Placebo
Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Drug: VIB4920 · Drug: Placebo
Intravenous Dose 1.
Also known as: Dazodalibep
Intravenous dose matched to VIB4920.
Population 1: Change From Baseline in ESSDAI at Day 169
The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.
Time frame: Baseline and Day 169
Population 2: Change From Baseline in ESSPRI at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.
Time frame: Baseline and Day 169
Population 1: Change From Baseline in ESSPRI at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.
Time frame: Baseline and Day 169
Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169
The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms. ESSEDAI\[3\] and \[4\] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.
Time frame: Day 169
Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169
The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.
Time frame: Baseline and Day 169
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169
The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.
Time frame: Baseline and Day 169
Patient Global Impression of Severity (PGIS) Score at Day 169
The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.
Time frame: Baseline and Day 169
Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.
Time frame: Day 169
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: Up to approximately 365 days
Serum Concentration of VIB4920
Blood samples were collected at the specified time points.
Time frame: Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365
Participants were recruited across 70 international sites between November 2019 and March 2023.
| Milestone | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo |
|---|---|---|---|---|
| Started | 38 | 36 | 55 | 54 |
| Completed stage i | 37 | 34 | 52 | 49 |
| Completed | 35 | 32 | 47 | 47 |
| Not completed | 3 | 4 | 8 | 7 |
| Withdrew: Non-compliance with procedures | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 4 | 6 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.
| Score on scale | Population 1: Placebo | Population 1: VIB4920 |
|---|---|---|
| Population 1: Change From Baseline in ESSDAI at Day 169 | -4.1 ± 0.6 | -6.3 ± 0.6 |
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.
| Score on scale | Population 2: Placebo | Population 2: VIB4920 |
|---|---|---|
| Population 2: Change From Baseline in ESSPRI at Day 169 | -0.53 ± 0.23 | -1.80 ± 0.23 |
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.
| Score on scale | Population 1: Placebo | Population 1: VIB4920 |
|---|---|---|
| Population 1: Change From Baseline in ESSPRI at Day 169 | -1.12 ± 0.29 | -1.80 ± 0.31 |
The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms. ESSEDAI\[3\] and \[4\] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.
| Participants | Population 1: Placebo | Population 1: VIB4920 |
|---|---|---|
| ESSDAI[3] Day 169 | 22 | 26 |
| ESSDAI[4] Day 169 | 18 | 24 |
The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.
| Score on scale | Population 1: Placebo | Population 1: VIB4920 | Population 2: Placebo | Population 2: VIB4920 |
|---|---|---|---|---|
| Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169 | 5.8 ± 1.6 | 8.1 ± 1.6 | 2.8 ± 1.4 | 8.1 ± 1.4 |
The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.
| Score on scale | Population 1: Placebo | Population 1: VIB4920 | Population 2: Placebo | Population 2: VIB4920 |
|---|---|---|---|---|
| Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169 | -14.02 ± 3.06 | -16.00 ± 3.22 | -8.52 ± 2.94 | -13.95 ± 2.95 |
The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.
| Score on scale | Population 1: Placebo | Population 1: VIB4920 | Population 2: Placebo | Population 2: VIB4920 |
|---|---|---|---|---|
| Patient Global Impression of Severity (PGIS) Score at Day 169 | -0.5 ± 0.1 | -0.6 ± 0.1 | -0.4 ± 0.1 | -0.6 ± 0.1 |
The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.
| Participants | Population 2: Placebo | Population 2: VIB4920 |
|---|---|---|
| Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169 | 18 | 36 |
An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).
| Participants | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo |
|---|---|---|---|---|
| Stage 1 TEAEs | 23 | 28 | 38 | 37 |
| Stage 1 SAEs | 0 | 1 | 1 | 3 |
| Stage 1 Grade ≥ 3 | 0 | 2 | 1 | 2 |
| Stage 1 Fatal AEs | 0 | 1 | 0 | 0 |
| Stage 2 TEAEs | 28 | 25 | 34 | 32 |
| Stage 2 SAEs | 1 | 3 | 1 | 2 |
| Stage 2 Grade ≥ 3 | 0 | 2 | 0 | 3 |
| Stage 2 Fatal AEs | 0 | 0 | 0 | 0 |
Blood samples were collected at the specified time points.
| mg/L | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo |
|---|---|---|---|---|
| Day 1 pre-dose | — | 0.002 ± 0.013 | — | 0.002 ± 0.013 |
| Day 1 post-dose | — | 470.370 ± 111.047 | — | 496.984 ± 182.915 |
| Day 15 | — | 97.058 ± 26.480 | — | 111.636 ± 56.244 |
| Day 29 | — | 128.228 ± 31.805 | — | 141.365 ± 100.163 |
| Day 57 | — | 62.363 ± 25.562 | — | 80.093 ± 64.358 |
| Day 85 | — | 53.716 ± 21.300 | — | 68.812 ± 60.349 |
| Day 113 | — | 52.796 ± 29.229 | — | 66.778 ± 59.558 |
| Day 141 pre-dose | — | 49.318 ± 27.952 | — | 80.912 ± 125.684 |
| Day 141 post-dose | 0.577 ± NA | 525.702 ± 155.286 | 25.004 ± NA | 532.216 ± 241.670 |
| Day 169 pre-dose | — | 50.390 ± 18.717 | — | 54.031 ± 30.161 |
| Day 169 post-dose | 469.366 ± 92.413 | 65.459 ± 113.805 | 572.071 ± 200.235 | 57.018 ± 31.592 |
| Day 197 | 39.535 ± 16.655 | 10.808 ± 9.982 | 39.399 ± 15.325 | 14.958 ± 28.728 |
| Day 225 | 46.885 ± 21.633 | 1.903 ± 1.594 | 73.173 ± 194.836 | 1.979 ± 1.624 |
| Day 253 | 45.069 ± 23.143 | 0.360 ± 0.343 | 63.950 ± 77.006 | 0.427 ± 0.485 |
| Day 281 | 46.368 ± 23.349 | 0.086 ± 0.160 | 54.050 ± 50.595 | 0.139 ± 0.340 |
| Day 309 | 52.409 ± 23.754 | 0.008 ± 0.026 | 44.732 ± 24.888 | 0.018 ± 0.044 |
| Day 365 | 2.446 ± 2.536 | 0 ± 0 | 1.531 ± 1.017 | 0.003 ± 0.014 |
Collected over Up to approximately 365 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Population 1: Placebo (Stage I) | 0/38 (0%) | 0/38 (0%) | 18/38 (47.4%) |
| Population 1: VIB4920 (Stage I) | 1/36 (2.8%) | 1/36 (2.8%) | 20/36 (55.6%) |
| Population 1: VIB4920 (Stage II) | 0/37 (0%) | 1/37 (2.7%) | 24/37 (64.9%) |
| Population 1: Placebo (Stage II) | 0/34 (0%) | 3/34 (8.8%) | 22/34 (64.7%) |
| Population 2: Placebo (Stage I) | 0/55 (0%) | 1/55 (1.8%) | 21/55 (38.2%) |
| Population 2: VIB4920 (Stage I) | 0/54 (0%) | 3/54 (5.6%) | 21/54 (38.9%) |
| Population 2: VIB4920 (Stage II) | 0/52 (0%) | 1/52 (1.9%) | 20/52 (38.5%) |
| Population 2: Placebo (Stage II) | 0/49 (0%) | 2/49 (4.1%) | 21/49 (42.9%) |
| Event | Population 1: Placebo (Stage I) | Population 1: VIB4920 (Stage I) | Population 1: VIB4920 (Stage II) | Population 1: Placebo (Stage II) | Population 2: Placebo (Stage I) | Population 2: VIB4920 (Stage I) | Population 2: VIB4920 (Stage II) | Population 2: Placebo (Stage II) |
|---|---|---|---|---|---|---|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 0/38 | 0/36 | 0/37 | 1/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/38 | 0/36 | 0/37 | 1/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Cervical dysplasiaReproductive system and breast disorders | 0/38 | 0/36 | 0/37 | 1/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Deep vein thrombosisVascular disorders | 0/38 | 0/36 | 0/37 | 1/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| DeathGeneral disorders | 0/38 | 1/36 | 0/37 | 0/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| COVID-19Infections and infestations | 0/38 | 1/36 | 0/37 | 0/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Cholecystitis chronicHepatobiliary disorders | 0/38 | 0/36 | 1/37 | 0/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Urinary tract infectionInfections and infestations | 0/38 | 0/36 | 0/37 | 0/34 | 0/55 | 0/54 | 0/52 | 1/49 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 0/36 | 0/37 | 0/34 | 0/55 | 0/54 | 0/52 | 1/49 |
| Atrial flutterCardiac disorders | 0/38 | 0/36 | 0/37 | 0/34 | 0/55 | 0/54 | 1/52 | 0/49 |
| Event | Population 1: Placebo (Stage I) | Population 1: VIB4920 (Stage I) | Population 1: VIB4920 (Stage II) | Population 1: Placebo (Stage II) | Population 2: Placebo (Stage I) | Population 2: VIB4920 (Stage I) | Population 2: VIB4920 (Stage II) | Population 2: Placebo (Stage II) |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/38 | 4/36 | 6/37 | 6/34 | 7/55 | 8/54 | 9/52 | 5/49 |
| Upper respiratory tract infectionInfections and infestations | 2/38 | 3/36 | 5/37 | 5/34 | 4/55 | 2/54 | 2/52 | 2/49 |
| HeadacheNervous system disorders | 5/38 | 4/36 | 4/37 | 2/34 | 2/55 | 2/54 | 4/52 | 1/49 |
| NasopharyngitisInfections and infestations | 0/38 | 1/36 | 3/37 | 0/34 | 5/55 | 5/54 | 2/52 | 6/49 |
| DiarrhoeaGastrointestinal disorders | 0/38 | 3/36 | 2/37 | 3/34 | 0/55 | 3/54 | 1/52 | 0/49 |
| Ligament sprainInjury, poisoning and procedural complications | 0/38 | 3/36 | 0/37 | 0/34 | 0/55 | 0/54 | 1/52 | 0/49 |
| DizzinessNervous system disorders | 1/38 | 3/36 | 1/37 | 0/34 | 0/55 | 0/54 | 0/52 | 0/49 |
| Oral herpesInfections and infestations | 2/38 | 0/36 | 3/37 | 0/34 | 0/55 | 0/54 | 0/52 | 1/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/38 | 0/36 | 3/37 | 2/34 | 1/55 | 0/54 | 1/52 | 3/49 |
| SyncopeNervous system disorders | 1/38 | 0/36 | 3/37 | 0/34 | 0/55 | 0/54 | 0/52 | 0/49 |
Full Analysis Set (FAS): included all randomized participants who received any dose of investigational product, analyzed according to the randomized treatment.
| Age, Customized(participants) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| 18-85 years | 38 | 36 | 55 | 54 | 183 |
| Sex: Female, Male(Participants) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| Female | 38 | 35 | 50 | 53 | 176 |
| Male | 0 | 1 | 5 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 23 | 22 | 61 |
| Not Hispanic or Latino | 30 | 28 | 32 | 32 | 122 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 11 | 9 | 25 |
| Asian | 0 | 2 | 5 | 11 | 18 |
| Black or African American | 1 | 3 | 3 | 4 | 11 |
| White | 34 | 26 | 31 | 23 | 114 |
| Other | 2 | 1 | 5 | 7 | 15 |
| Population 1: Baseline ESSDAI Total Score(score on scale) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| Mean | 10.1 ± 4.1 | 11.4 ± 4.5 | — | — | 10.7 ± 4.3 |
| Population 2: Baseline ESSPRI Total Score(score on a scale) | Population 1: Placebo/VIB4920 | Population 1: VIB4920/Placebo | Population 2: Placebo/VIB4920 | Population 2: VIB4920/Placebo | Total |
|---|---|---|---|---|---|
| Mean | — | — | 6.8 ± 1.2 | 7.1 ± 1.6 | 6.9 ± 1.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Sep 2022, 32 months.
Results were first posted in Apr 2025, 2 years 7 months after primary completion. A results delay was requested in May 2023.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazodalibep